Clinical trials: AI
Well Child Visit, Gaps in Care
A Trial of AI-Powered Text Message Outreach on Well-Child Visit Completion
The goal of this clinical trial is to evaluate whether conversational AI-powered text message outreach with appointment scheduling assistance improves well-child visit completion rates in Medicaid-enrolled children aged 0-21…
- Trial name
- HEDIS (NCT06698640)
- Testing
- Automated SMS, Automated SMS + Conversational AI Scheduling Assistance, Traditional Passive Outreach
- Where
- United States
- Volunteers
- 2,821 people
- Sponsor
- Waymark
Physician Workflow, Artificial Intelligence (AI)
A Randomized Controlled Trial of Ambient Artificial Intelligence Scribe Technologies
This is a three-arm pragmatic RCT of 238 outpatient physicians at a large academic health system, randomized 1:1:1 to one of two AI scribe tools or a usual-care control group.
- Trial name
- AIScribe RCT (NCT06792890)
- Testing
- Use Nabla AI Scribe tool provided, Use AI Scribe tool provided by Vendor B
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- University of California, Los Angeles
Cystic Fibrosis
Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis (CF) Patients With Pseudomonas Aeruginosa (PA)
The purpose of this study was to evaluate the safety and efficacy of multiple courses of AZLI in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).
- Trial name
- AIR-CF3 (NCT00128492)
- Testing
- AZLI 75 mg two times a day (BID)/ three times a day (TID)
- Where
- 65 sites in United States, Australia and 2 more
- Volunteers
- 274 people
- Sponsor
- Gilead Sciences
Breast Cancer
A Study of HR+/HER2- Metastatic Breast Cancer Patients Treated With Palbociclib Together With an Aromatase Inhibitor From 2017 to 2023 in Denmark.
The purpose of this study is to describe the effect of the medicine palbociclib when given together with an aromatase inhibitor for treatment of breast cancer.
- Trial name
- NCT06307457
- Testing
- Palbociclib in combination with AI
- Where
- Denmark
- Volunteers
- 604 people
- Sponsor
- Pfizer
Bone Age
Validation of an Artificial Intelligence-based Algorithm for Skeletal Age Assessment
The purpose of this study is to understand the effects of using an Artificial Intelligence algorithm for skeletal age estimation as a computer-aided diagnosis (CADx) system.
- Trial name
- NCT03530098
- Testing
- BoneAgeModel
- Where
- 6 sites in United States
- Volunteers
- 1,903 people
- Sponsor
- Stanford University
Type 1 Diabetes, Type 2 Diabetes
ACCESS: AI for pediatriC diabetiC Eye examS Study
The purpose of this study is to determine if providing in clinic point-of-care autonomous AI diabetic retinopathy exams improves screening rates compared to standard of care referral to an eye care provider, in a randomized…
- Trial name
- ACCESS (NCT05131451)
- Testing
- Point of Care Autonomous AI diabetic retinopathy exam
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- Johns Hopkins University
Cancer
Assessing the Performance of Artificial Intelligence (AI)-Augmented Electronic Health Record (EHR) Data Abstraction for Clinical Trial Patient Screening
Identifying eligible patients is a key process in the clinical trial enterprise. Currently, this process relies on time-intensive manual chart review, creating a rate-limiting step for trial participation.
- Trial name
- NCT06561217
- Testing
- Chart review
- Where
- 2 sites in United States
- Volunteers
- 355 people
- Sponsor
- University of Pennsylvania
ER+ Breast Cancer
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
The addition of entinostat to an AI will result in a maximal abrogation of estrogen receptor-α mediated activity and inhibit mechanisms of resistance to the aromatase inhibitor.
- Trial name
- NCT00828854
- Testing
- Entinostat, Aromatase Inhibitor (AI) Therapy
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Syndax Pharmaceuticals
Type 1 Diabetes
The Pediatric Artificial Pancreas Automated Initialization Trial
The goal of this clinical trial is to obtain safety data and exploratory glycemic control data from use of an at-home closed loop control (CLC) system (t:slim X2 with Control-IQ Technology) with periodic parameter adjustments…
- Trial name
- PEDAP-AI (NCT06017089)
- Testing
- AI-based Advisor system
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Marc Breton